Moderna Shares Slump 10% on Profit-Taking Following Cancer Vaccine Rally

Key Facts

1Moderna stock fell 10% to $214 as profit-taking hit the shares following a significant rally driven by cancer vaccine optimism.

Moderna stock fell 10% to $214 as profit-taking hit the shares following a significant rally driven by cancer vaccine optimism. 247wallst.com reported that the decline follows a period of outperformance, with investors locking in profits ahead of critical clinical trial readouts expected later this month.

MRNA closed at $236.50 on October 15, 2026, while PFE closed at $29.44 on the same date. According to company statements, Moderna reported Q2 revenue of $145 million and a loss of $1.97 per share, meeting expectations, while management guidance projects revenue growth of up to 10% for the full year 2026.